Clinical Report: Progress in Breast Cancer Chemotherapy: Predictive Biomarkers, Mechanisms of Resistance, and Treatment Approaches
Overview
This editorial summarizes advancements in breast cancer chemotherapy, focusing on predictive biomarkers, resistance mechanisms, and treatment strategies. Key findings include the efficacy of pentoxifylline and trimetazidine in reducing chemotherapy-induced neuropathy.
Background
Breast cancer remains the most commonly diagnosed cancer among women and a leading cause of cancer-related mortality. The evolution of chemotherapy has been critical in managing various breast cancer subtypes, particularly in high-risk and triple-negative cases. Understanding predictive biomarkers and resistance mechanisms is essential for treatment optimization.
Data Highlights
No specific numerical data presented in the editorial.
Key Findings
Pentoxifylline significantly reduced the incidence of grade 2 or higher peripheral sensory neuropathy in patients undergoing AC/T chemotherapy.
Trimetazidine decreased the incidence of grade 2–3 paclitaxel-induced peripheral neuropathy.
The Systemic Immune-Inflammation Index (SII) may serve as a prognostic tool for breast cancer incidence and mortality.
High biopsy-sTILs and Ki67 levels are predictive of pathological complete response in triple-negative breast cancer patients.
Clinical Implications
The findings highlight the potential of pentoxifylline and trimetazidine to reduce chemotherapy-related side effects.
Conclusion
This editorial summarizes advancements in breast cancer chemotherapy, focusing on predictive biomarkers and resistance mechanisms.
